**Results Comment** 

## Bangkok Chain Hospital (BCH TB) - BUY, Price Bt20.4, TP Bt30

Siriporn Arunothai | Email: siriporn.aru@thanachartsec.co.th

## Very strong 3Q21, beat expectation

- BCH reported Bt2.9bn net profit in 3Q21, up 601% y-y and 153% q-q. This was better than our earnings preview and the Street's earnings forecast due to its higher-than-expected revenue and margin.
- Its strong earnings growth was mainly driven by COVID-19 services. Top line grew by 237% y-y and 85% q-q to Bt8.0bn in 3Q21. Revenue from general patients (including revenue from COVID-19 services) grew by 398% y-y and 101% q-q. Revenue from Social Security Scheme (SSS) declined by 18% y-y but up 3% q-q. The weak SSS revenue resulted from a drop in severity cases and the delay of payment for Risk Adjusted Capitation revenue from 3Q21 to 4Q21.
- Its operating margin also expanded to 49% in 3Q21 from 24.9% in 3Q20 and 37% in 2Q21 due to strong revenue growth and operating leverage benefits.
- 9M21 earnings accounted for 142% of our full-year earnings forecast. We expect its strong earnings to continue in 4Q21F due to a new source of income from the Moderna vaccine, remaining high Covid-19 cases, despite falling from its peak in 3Q21 and rising non-COVID patients.
- With an earnings upside, together with its valuation not fully valued, we maintain BUY on BCH.

| Income Statement             |        |        |        | (consolidated) |                  | Income Statement         |       |      | 9M as   |        |        |
|------------------------------|--------|--------|--------|----------------|------------------|--------------------------|-------|------|---------|--------|--------|
| Yr-end Dec (Btm)             | 3Q20   | 4Q20   | 1Q21   | 2Q21           | 3Q21             | (Bt m)                   | q-q%  | у-у% | % 2021F | 2021F  | 2022F  |
| Revenue                      | 2,359  | 2,308  | 2,316  | 4,313          | 7,959            | Revenue                  | 85    | 237  | 82      | 17,889 | 11,108 |
| Gross profit                 | 863    | 737    | 698    | 1,995          | 4,271            | Gross profit             | 114   | 395  | 123     | 5,648  | 3,464  |
| SG&A                         | 276    | 363    | 291    | 401            | 367              | SG&A                     | (8)   | 33   | 61      | 1,737  | 1,368  |
| Operating profit             | 587    | 374    | 407    | 1,594          | 3,904            | Operating profit         | 145   | 566  | 151     | 3,911  | 2,096  |
| EBITDA                       | 791    | 583    | 623    | 1,799          | 4,124            | EBITDA                   | 129   | 421  | 137     | 4,783  | 2,996  |
| Other income                 | 19     | 35     | 68     | 18             | 19               | Other income             | 4     | (1)  | 18      | 572    | 897    |
| Other expense                | 0      | 0      | 0      | 0              | 0                | Other expense            |       |      | na      | 0      | 0      |
| Interest expense             | 35     | 35     | 28     | 35             | 40               | Interest expense         | 14    | 16   | 80      | 129    | 106    |
| Profit before tax            | 571    | 373    | 447    | 1,577          | 3,882            | Profit before tax        | 146   | 580  | 136     | 4,354  | 2,887  |
| Income tax                   | 107    | 68     | 84     | 312            | 772              | Income tax               | 148   | 624  | 137     | 853    | 554    |
| Equity & invest. income      | 1      | 1      | 1      | 1              | 0                | Equity & invest. income  | (87)  | (87) | 73      | 2      | 2      |
| Minority interests           | (52)   | (28)   | (40)   | (121)          | (215)            | Minority interests       | na    | na   | 88      | (425)  | (271)  |
| Extraordinary items          | 0      | 0      | 0      | 0              | 0                | Extraordinary items      |       |      | na      | 0      | 0      |
| Net profit                   | 413    | 278    | 324    | 1,146          | 2,896            | Net profit               | 153   | 601  | 142     | 3,077  | 2,064  |
| Normalized profit            | 413    | 278    | 324    | 1,146          | 2,896            | Normalized profit        | 153   | 601  | 142     | 3,077  | 2,064  |
| EPS (Bt)                     | 0.17   | 0.11   | 0.13   | 0.46           | 1.16             | EPS (Bt)                 | 153   | 601  | 142     | 1.23   | 0.83   |
| Normalized EPS (Bt)          | 0.17   | 0.11   | 0.13   | 0.46           | 1.16             | Normalized EPS (Bt)      | 153   | 601  | 142     | 1.23   | 0.83   |
| Balance Sheet (consolidated) |        |        |        |                | Financial Ratios |                          |       |      |         |        |        |
| Yr-end Dec (Btm)             | 3Q20   | 4Q20   | 1Q21   | 2Q21           | 3Q21             | (%)                      | 3Q20  | 4Q20 | 1Q21    | 2Q21   | 3Q21   |
| Cash & ST investment         | 757    | 946    | 1,713  | 1,995          | 2,290            | Sales grow th            | (4.5) | 5.1  | 6.4     | 107.1  | 237.4  |
| A/C receivable               | 2,450  | 2,303  | 1,739  | 3,181          | 6,573            | Operating profit grow th | 4.4   | 9.7  | 10.1    | 288.0  | 565.5  |
| Inventory                    | 244    | 250    | 227    | 249            | 286              | EBITDA grow th           | 8.2   | 13.7 | 14.1    | 199.1  | 421.1  |
| Other current assets         | 43     | 40     | 67     | 62             | 2,635            | Norm profit grow th      | 2.8   | 15.6 | 24.9    | 311.3  | 600.7  |
| Investment                   | 29     | 32     | 34     | 33             | 32               | Norm EPS grow th         | 2.8   | 15.6 | 24.9    | 311.3  | 600.7  |
| Fixed assets                 | 11,262 | 11,438 | 11,437 | 11,455         | 11,533           |                          |       |      |         |        |        |
| Other assets                 | 1,578  | 1,519  | 1,520  | 1,527          | 1,518            | Gross margin             | 36.6  | 31.9 | 30.1    | 46.3   | 53.7   |
| Total assets                 | 16,364 | 16,527 | 16,736 | 18,503         | 24,867           | Operating margin         | 24.9  | 16.2 | 17.6    | 37.0   | 49.0   |
| S-T debt                     | 4,355  | 2,787  | 1,760  | 860            | 1,125            | EBITDA margin            | 33.5  | 25.3 | 26.9    | 41.7   | 51.8   |
| A/C payable                  | 515    | 565    | 535    | 885            | 1,471            | Norm net margin          | 17.5  | 12.1 | 14.0    | 26.6   | 36.4   |
| Other current liabilities    | 796    | 2,316  | 830    | 2,602          | 5,279            |                          |       |      |         |        |        |
| L-T debt                     | 3,060  | 2,946  | 5,344  | 5,006          | 5,133            | D/E (x)                  | 1.1   | 0.8  | 1.0     | 0.7    | 0.6    |
| Other liabilities            | 299    | 288    | 264    | 262            | 237              | Net D/E (x)              | 1.0   | 0.7  | 0.7     | 0.5    | 0.4    |
| Minority interest            | 719    | 742    | 785    | 845            | 1,064            | Interest coverage (x)    | 22.8  | 16.7 | 22.6    | 51.2   | 102.8  |
| Shareholders' equity         | 6,621  | 6,885  | 7,218  | 8,043          | 10,559           | Interest rate            | 1.9   | 2.1  | 1.7     | 2.2    | 2.6    |
| Working capital              | 2,180  | 1,988  | 1,430  | 2,546          | 5,389            | Effective tax rate       | 18.7  | 18.1 | 18.8    | 19.7   | 19.9   |
| Total debt                   | 7,414  | 5,732  | 7,104  | 5,866          | 6,257            | ROA                      | 10.3  | 6.8  | 7.8     | 26.0   | 53.4   |
| Netdebt                      | 6,657  | 4,787  | 5,392  | 3,871          | 3,967            | ROE                      | 25.3  | 16.5 | 18.4    | 60.1   | 124.6  |

Sources: Company data, Thanachart estimates

## **General Disclaimers And Disclosures:**

This report is prepared and issued by Thanachart Securities Public Company Limited (TNS) as a resource only for clients of TNS, Thanachart Capital Public Company Limited (TCAP) and its group companies. Copyright © Thanachart Securities Public Company Limited. All rights reserved. The report may not be reproduced in whole or in part or delivered to other persons without our written consent.

This report is prepared by analysts who are employed by the research department of TNS. While the information is from sources believed to be reliable, neither the information nor the forecasts shall be taken as a representation or warranty for which TNS or TCAP or its group companies or any of their employees incur any responsibility. This report is provided to you for informational purposes only and it is not, and is not to be construed as, an offer or an invitation to make an offer to sell or buy any securities. Neither TNS, TCAP nor its group companies accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.

The information and opinions contained herein have been compiled or arrived at from sources believed reliable. However, TNS, TCAP and its group companies make no representation or warranty, express or implied, as to their accuracy or completeness. Expressions of opinion herein are subject to change without notice. The use of any information, forecasts and opinions contained in this report shall be at the sole discretion and risk of the user.

TNS, TCAP and its group companies perform and seek to perform business with companies covered in this report. TNS, TCAP, its group companies, their employees and directors may have positions and financial interest in securities mentioned in this report. TNS, TCAP or its group companies may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any entity mentioned in this report. Therefore, investors should be aware of conflict of interest that may affect the objectivity of this report.

Note: Thanachart Securities Public Company Limited act as a Market Maker and Derivative Warrants Issuer. At present, TNS has issued 149 Derivative ACE16C2111A, ACE16C2201A, ACE16C2202A, ADVA16C2110A, ADVA16C2201A, ADVA16C2202A, AEON16C2201A, Warrants which are AEON16C2201B, AMAT16C2112A, AOT16C2112A, AOT16C2202A, BAM16C2110A, BAM16C2112A, BANP16C2110A, BANP16C2112A, BANP16C2201A, BANP16C2202A, BBL16C2201A, BCH16C2111A, BCH16C2111B, BCH16C2201A, BCH16C2203A, BCPG16C2111A. CHG16C2112A, BEC16C2202A, BGRI16C2110A, BGRI16C2112A, CBG16C2201A, CBG16C2202A, CHG16C2111A, CHG16C2202A, COM716C2110A, COM716C2112A, CPAL16C2111A, CPAL16C2112A, CPF16C2112A, CPN16C2202A, DELT16C2112A, DELT16C2202A, DELT16C2203A, DOHO16C2111A, DOHO16C2112A, DOHO16C2202A, DTAC16C2112A, EA16C2110A, EA16C2201A, EGCO16C2110A, ESSO16C2202A, GLOB16C2201A, GLOB16C2203A, GPSC16C2110A, GPSC16C2201A, GPSC16C2201B, GPSC16C2203A, GULF16C2112A, GULF16C2202A, GUNK16C2110A, GUNK16C2112A, GUNK16C2201A, GUNK16C2203A, HANA16C2112A, HANA16C2202A, HMPR16C2202A, INTU16C2201A, INTU16C2202A, IRPC16C2110A, IRPC16C2112A, IVL16C2110A, IVL16C2111A, IVL16C2202A, JAS16C2202A, JMAR16C2111A, JMAR16C2201A, JMAR16C2202A, JMT16C2110A, JMT16C2201A, JMT16C2203A, KBAN16C2111A, KBAN16C2111B, KBAN16C2201A, KBAN16C2202A, KCE16C2110A, KCE16C2201A, KTC16C2110A, KTC16C2110B, KTC16C2112A, KTC16C2202A, LH16C2202A, MAJO16C2201A, MEGA16C2112A, MINT16C2112A, MTC16C2112A, MTC16C2202A, OR16C2112A, OR16C2202A, OR16C2203A, PTG16C2201A, PTG16C2202A, PTG16C2203A, PTL16C2201A, PTL16C2202A, PTL16C2202B, PTT16C2112A, PTT16C2201A, PTTE16C2112A, PTTG16C2110A, PTTG16C2111A, RBF16C2110A, RBF16C2112A, RBF16C2202A, RS16C2112A, RS16C2201A, S5016C2112A, S5016C2112A, S5016C2112B, S5016C2112C. S5016P2112C, S5016P2112A, S5016P2112B, S5016C2203A, S5016P2203A, S5016C2112D, S5016P2112D, SAWA16C2112A, SAWA16C2202A, SCB16C2111A, SCB16C2112A, SCB16C2201A, SCB16C2202A, SCC16C2112A, SCGP16C2202A, SCGP16C2201A, SPAL16C2202A, SPRC16C2201A, STA16C2112A, STA16C2201A, STEC16C2110A, STEC16C2201A, STGT16C2111A, STGT16C2202A, SYNE16C2202A, TASC16C2201A, TOP16C2112A, TOP16C2202A, TRUE16C2202A, TRUE16C2203A, TU16C2110A, TU16C2111A, TU16C2202A, WHA16C2202A (underlying securities are ACE, ADVANC, AEONTS, AMATA, AOT, BAM, BANPU, BBL, BCH, BCPG, BEC, BGRIM, CBG, CHG, COM7, CPALL, CPF, CPN, DELTA, DOHOME, DTAC, EA, EGCO, ESSO, GLOBAL, GPSC, GULF, GUNKUL, HANA, HMPRO, INTUCH, IRPC, IVL, JAS, JMART, JMT, KBANK, KCE, KTC, LH, MAJOR, MEGA, MINT, MTC, OR, PTG, PTL, PTT, PTTEP, PTTGC, RBF, RS, SAWAD, SCB, SCC, SCGP, SPALI, SPRC, SET50, STA, STEC, STGT, SYNTEC, TASCO, TOP, TRUE, TU, WHA). Since TNS covers those underlying securities in research report, consequently TNS incurs conflicts of interest. Moreover, Investors are advised to carefully review the details and information in the prospectus before making investment decisions.

**Note:** Thanachart Securities has an indirect financial interest in Ratchthani Leasing PcI (THANI). Thanachart Securities PcI is a subsidiary of Thanachart Capital PcI (TCAP) which holds more than 56% of the shareholding in Ratchthani Leasing PcI (THANI).

**Note:** Thanachart Capital Public Company Limited (TCAP), TMBThanachart Bank Public Company Limited (TTB), are related companies to Thanachart Securities Public Company Limited (TNS). Thanachart Securities PcI is a subsidiary of Thanachart Capital PcI (TCAP) which holds 20.1% of the shareholding in TMBThanachart Bank PcI.

Thanachart Capital Public Company Limited (TCAP), Ratchthani Leasing Public Company Limited (THANI), TMB Public Company Limited, MBK PUBLIC COMPANY LIMITED (MBK) and PATUM RICE MILL AND GRANARY PUBLIC COMPANY LIMITED (PRG) are related companies to Thanachart Securities Public Company Limited (TNS). Since TNS covers those securities in research report, consequently TNS incurs conflicts of interest.

## Disclosure of Interest of Thanachart Securities

Investment Banking Relationship

Within the preceding 12 months, Thanachart Securities has lead-managed public offerings and/or secondary offerings (excluding straight bonds) of the securities of the following companies: Saksiam Leasing PcI. (SAK TB)